Axsome Therapeutics Inc (AXSM : NASDAQ)
Common Stock
$142.20
USD
-1.86 (-1.29%)
Last updated: 2026-10-27
Follow AXSM
AXSM
Axsome Therapeutics Inc
WealthAwesomePerformance
1 Day
-1.29%
1 Week
-10.89%
1 Month
-27.11%
YTD
-43.61%
Key Statistics
Market Cap
$7.55B
52W High
$260.19
52W Low
$123.50
P/E Ratio
-
50 Day MA
$190.45
200 Day MA
$199.95
Beta
0.85
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/27/2026 | $143.99 | $145.44 | $141.15 | $142.20 | $142.20 | 1,104,093 |
| 10/26/2026 | $145.29 | $145.34 | $142.00 | $144.06 | $144.06 | 878,979 |
| 10/23/2026 | $154.66 | $154.74 | $143.90 | $145.04 | $145.04 | 1,593,500 |
| 10/22/2026 | $156.13 | $158.08 | $154.24 | $156.07 | $156.07 | 832,345 |
| 10/21/2026 | $158.83 | $160.82 | $156.04 | $156.31 | $156.31 | 524,754 |
| 10/20/2026 | $157.65 | $164.79 | $157.38 | $159.58 | $159.58 | 653,261 |
| 10/19/2026 | $157.54 | $158.66 | $154.50 | $155.81 | $155.81 | 769,916 |
| 10/16/2026 | $160.43 | $160.43 | $156.09 | $157.14 | $157.14 | 873,100 |
| 10/15/2026 | $163.44 | $169.96 | $160.27 | $161.79 | $161.79 | 802,579 |
| 10/14/2026 | $156.44 | $164.00 | $155.18 | $162.22 | $162.22 | 893,237 |
Analyst Price Targets
Based on 22 analysts covering AXSM · as of Oct 26, 2026
Wall Street analysts forecast AXSM stock price to rise 97.1% over the next 12 months.
Consensus
Strong Buy4.77 / 5.00
Avg. Target
US$280.33
+97.1% Upside
Previously US$282.54 on Oct 16, 2026
Current Price
US$142.20
Last close
Analyst Breakdown (22 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on AXSM's historical volatility
30-Day Vol
38.1%
Annualized
90-Day Vol
40.2%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
US$118.95
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$133.98 | US$117.47 – US$152.82 |
| 60 trading days | US$126.24 | US$104.81 – US$152.05 |
| 90 trading days | US$118.95 | US$94.71 – US$149.38 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Axsome Therapeutics Inc
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.
Financials
- Revenue (TTM)
- $776.57M
- EBITDA
- $-172.92M
- Profit Margin
- -24.68%
- ROE (TTM)
- -245.10%
- EPS (Diluted)
- -3.74
- Book Value
- 1.59
Classification
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About AXSM.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| NUWE | Nuwellis Inc | $5.41 | +1590.63% |
| ENLV | Enlivex Therapeutics Ltd | $2.70 | +1460.69% |
| QETAR | Quetta Acquisition Corporation Right | $0.68 | +70.00% |
| BRAI | Braiin Limited Common Stock | $3.31 | +56.13% |
| IRHOR | Iron Horse Acquisitions Corp. II Rights | $0.14 | +49.83% |
| FSHPR | Flag Ship Acquisition Corp. Right | $0.10 | +47.06% |
| AEYE | AudioEye Inc | $10.14 | +36.66% |
| MBRX | Moleculin Biotech Inc | $9.27 | +30.77% |
AXSM.US news timeline
1 article covering AXSM.US, most recent first
Latest